22 July 2021 
EMA/CHMP/229665/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Vosevi 
sofosbuvir / velpatasvir / voxilaprevir 
On 22 July 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Vosevi. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted an extension to the indication for Vosevi as follows:2 
Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults 
patients aged 12 years and older and weighing at least 30 kg. 
The CHMP also recommended the addition of a new 200/50/50 mg strength for the film-coated tablets.  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment 
report (EPAR), and will be available in all official European Union languages after a decision on this 
change to the marketing authorisation has been granted by the European Commission.  
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 
67 days from adoption of the opinion 
2 New text in bold, removed text as strikethrough. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
 An agency of the European Union      
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
